 |
Only Enavail can offer you a range of particle engineering systems with all of the factors important to your compound development: high bioavailability, highest available potency, gentle processing for labile compounds, and versatility for multiple routes of administration.
Key Advantages: |
| |
|
|
|
The Enavail technologies have been utilized on over 20 compounds delivering superior performance and key advantages important to each compound. This chart highlights a portion of these compounds.
|
| Model Compounds Tested |
| Drug |
LogP |
Solubility |
Process |
Surface Area
(bulk m2/g) |
Surface Area
(processed m2/g) |
Super Sat. (C/Ceq) |
Potency |
| Carbamazepine |
2.9 |
15.2µg/ml |
RF,CP |
2.3 |
12.8 |
Increased Dissolution Rate |
50% |
| Cyclosporin A |
4.3 |
7.3µg/ml |
CP |
- |
9.5 |
18X |
90% |
| Danazol |
3.6 |
51.0µg/ml |
RF,CP |
0.5 |
83.1 |
Increased Dissolution Rate |
87% |
| Itraconazole |
6.2 |
~1ng/ml |
RF,CP |
2.9 |
61.3 |
10,000X |
33-86% |
| Ketoprofen |
3.2 |
51.0µg/ml |
CP |
- |
9.8 |
Increased Dissolution Rate |
90% |
| Naproxen |
2.8 |
15.9µg/ml |
CP |
- |
- |
Increased Dissolution Rate |
66% |
| Repaglinide |
5.1 |
2.1mg/ml |
RF,CP |
1.5 |
9.4 |
5.0X |
86% |
| Tacrolimus |
3.3 |
2.2µg/ml |
RF |
0.5 |
55.0 |
22.8X |
60% |
| BSA |
- |
Soluble |
RF |
1.0 |
134.0 |
High Stability |
100% |
| Insulin |
0.2 |
Slightly Soluble |
RF |
- |
- |
High Stability |
83% |
| Lysozyme |
- |
Soluble |
RF |
4.4 |
86.4 |
High Stability |
100% |
|
|
|
|
